Status:
TERMINATED
A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
Lead Sponsor:
EMD Serono
Conditions:
Relapsing Multiple Sclerosis
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
To evaluate the safety and tolerability of atacicept and to explore if atacicept reduces central nervous system inflammation in subjects with relapsing multiple sclerosis (RMS) as assessed by frequent...
Eligibility Criteria
Inclusion
- \- Diagnosis of RMS (as per McDonald criteria, 2005) Other protocol-defined inclusion criteria could apply.
Exclusion
- Have primary progressive multiple sclerosis (MS)
- Have secondary progressive MS without superimposed relapses
- Relevant cardiac, hepatic and renal diseases as specified in the protocol
- Pretreatment with immunosuppressants and immunomodulating drugs as specified in the protocol
- Clinical significant abnormalities in blood cell counts and immunoglobulin levels as specified in the protocol
- Clinical significant acute or chronic infections as specified in the protocol Other protocol-defined exclusion criteria could apply.
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT00642902
Start Date
April 1 2008
End Date
September 1 2009
Last Update
May 24 2016
Active Locations (50)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Phoenix, Arizona, United States
2
Research Site
Atlanta, Georgia, United States
3
Research Site
Northbrook, Illinois, United States
4
Research Site
East Lansing, Michigan, United States